Clinical Scorecard: Early doxycycline use may raise pregnancy loss risk

At a Glance

Key Highlights

• In respiratory tract infection cohorts, doxycycline was associated with higher adjusted relative risks of pregnancy loss than amoxicillin in both claims databases.
• Comparisons with macrolides also showed higher adjusted relative risks of pregnancy loss among doxycycline-exposed patients with respiratory tract infections.
• For acne, an association was observed in MarketScan but not in the Medicaid analysis.
• The retrospective observational design cannot establish causation; residual confounding and exposure misclassification remain possible.
• The study did not evaluate congenital malformations, and stillbirth-specific findings were inconclusive because of small event numbers.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

• The source provides no specific monitoring recommendations.

Risks

Patient & Prescribing Data

For respiratory tract infections, pregnancy loss occurred in 32% versus 20% of doxycycline- versus amoxicillin-exposed pregnancies in MarketScan, and 27% versus 19% in Medicaid. Compared with macrolides, rates were 32% versus 22% in MarketScan and 27% versus 20% in Medicaid. For acne, rates were 27% versus 18% in MarketScan and about 20% in both groups in Medicaid.

Clinical Best Practices

• Weigh the potential benefits and risks of doxycycline when considering treatment during early pregnancy, as advised by the study authors.
• Interpret the reported associations in light of the observational design and the possibility of residual confounding.
• Do not infer congenital-malformation risk from this study; congenital malformations were not evaluated.

Related Resources & Content

• Annals of Internal Medicine study, as described in the source article